| Literature DB >> 33127292 |
Aurélien Perrin1, Raul Juntas Morales2, François Rivier3, Claude Cances4, Ulrike Walther-Louvier3, Charles Van Goethem1, Corinne Thèze1, Delphine Lacourt1, Henri Pégeot1, Reda Zenagui1, Emmanuelle Uro-Coste5, Nicolas Leboucq6, Edoardo Malfatti7, Constance Delaby8, Sylvain Lehmann8, Valérie Rigau9, Michel Koenig1, Mireille Cossée10.
Abstract
Next generation sequencing (NGS) has allowed the titin gene (TTN) to be identified as a major contributor to neuromuscular disorders, with high clinical heterogeneity. The mechanisms underlying the phenotypic variability and the dominant or recessive pattern of inheritance are unclear. Titin is involved in the formation and stability of the sarcomeres. The effects of the different TTN variants can be harmless or pathogenic (recessive or dominant) but the interpretation is tricky because the current bioinformatics tools can not predict their functional impact effectively. Moreover, TTN variants are very frequent in the general population. The combination of deep phenotyping associated with RNA molecular analyses, western blot (WB) and functional studies is often essential for the interpretation of genetic variants in patients suspected of titinopathy. In line with the current guidelines and suggestions, we implemented for patients with skeletal myopathy and with potentially disease causing TTN variant(s) an integrated genotype-transcripts-protein-phenotype approach, associated with phenotype and variants segregation studies in relatives and confrontation with published data on titinopathies to evaluate pathogenic effects of TTN variants (even truncating ones) on titin transcripts, amount, size and functionality. We illustrate this integrated approach in four patients with recessive congenital myopathy.Entities:
Keywords: Congenital myopathy; Deep phenotyping; Titin transcripts; Titin western-blot; Titinopathy
Year: 2020 PMID: 33127292 DOI: 10.1016/j.nmd.2020.09.032
Source DB: PubMed Journal: Neuromuscul Disord ISSN: 0960-8966 Impact factor: 4.296